PDCD1 and neoplasm: The in vivo investigations conducted on C57BL/6 mice, using doses of 50 or 100 mg/kg, revealed that the tumor-inhibitory effect of EGCG was facilitated by CD8+ T cells and was equivalent to the effects of anti-PD-1 treatment.